Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Coherus Oncology (CHRS) over the last 12 years, with Q3 2025 value amounting to $9.2 million.

  • Coherus Oncology's Receivables - Net fell 9448.25% to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.2 million, marking a year-over-year decrease of 9448.25%. This contributed to the annual value of $111.3 million for FY2024, which is 5726.89% down from last year.
  • As of Q3 2025, Coherus Oncology's Receivables - Net stood at $9.2 million, which was down 9448.25% from $5.1 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Receivables - Net ranged from a high of $260.5 million in Q4 2023 and a low of $5.1 million during Q2 2025
  • For the 5-year period, Coherus Oncology's Receivables - Net averaged around $130.3 million, with its median value being $123.0 million (2021).
  • Per our database at Business Quant, Coherus Oncology's Receivables - Net skyrocketed by 14833.03% in 2024 and then plummeted by 9708.48% in 2025.
  • Coherus Oncology's Receivables - Net (Quarter) stood at $123.0 million in 2021, then decreased by 10.61% to $110.0 million in 2022, then surged by 136.92% to $260.5 million in 2023, then tumbled by 57.27% to $111.3 million in 2024, then plummeted by 91.7% to $9.2 million in 2025.
  • Its Receivables - Net stands at $9.2 million for Q3 2025, versus $5.1 million for Q2 2025 and $60.5 million for Q1 2025.